Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure

Movement Disorders

Volumn 21, Issue 10, 2006, Pages 1578-1594

  Fox, Susan H ^a   Lang, Anthony E ^a   Brotchie, Jonathan M ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Animal models; Basal ganglia; Parkinson's disease; Pharmacology

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; BUSPIRONE; CANNABIS; CLONIDINE; CLOZAPINE; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DEXTROMETHORPHAN; DIZOCILPINE; FIPAMEZOLE; FLUVOXAMINE; IDAZOXAN; ISTRADEFYLLINE; LEVODOPA; MEMANTINE; METHYSERGIDE; NABILONE; NALOXONE; NALTREXONE; PAROXETINE; QUETIAPINE; RAUWOLSCINE; REMACEMIDE; RILUZOLE; RIMONABANT; SARIZOTAN; TALAMPANEL; TRAXOPRODIL; UNINDEXED DRUG; YOHIMBINE;

CHOREA; CLINICAL TRIAL; CONSENSUS; CONVULSION; DAILY LIFE ACTIVITY; DROWSINESS; DRUG DOSE REGIMEN; DRUG TARGETING; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FIBROSIS; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PREDICTION; PRIMATE; PRIORITY JOURNAL; RATING SCALE; REVIEW; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; VALIDATION PROCESS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; CLINICAL TRIALS, PHASE II; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; DYSKINESIA, DRUG-INDUCED; HAPLORHINI; HUMANS; TREATMENT FAILURE;

EID: 33750990196     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20936     Document Type: Review

References (152)

1. Mitchell U, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain: implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 1992;115: 809-824.
2. Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neurosci Lett 1986;63:61-65.
3. Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat Disord 2003;9:131-137.
4. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus: II, neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994;72:507-520.
5. Blanchet PJ, Calon F, Morissette M, et al. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord 2004;10:297-304.
6. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
7. Obeso JA, Rodriguez Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 2000;47:S22-S32.
8. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
9. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005;20:919-931.
10. Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Invest Drugs 2004;5:720-726.
11. Linazasoro G. Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Mov Disord 2004;19:743-754.
12. Davis CC, Williams AC, Markey SP, et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979;1:249-254.
13. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
14. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
15. Deutch AY, Elsworth JD, Goldstein M, et al. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci Lett 1986;68:51-56.
16. Jenner P, Rupniak NM, Rose S, et al. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 1984;50:85-90.
17. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 1984;292:390-394.
18. Clarke CE, Sambrook MA, Mitchell U, Crossman AR. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1987;78:273-280.
19. Falardeau P, Bouchard S, Bedard PJ, Boucher R, Di Paolo T. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 1988;150:59-66.
20. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 2003;61:S4-S11.
21. Boyce S, Clarke CE, Luquin R, et al. Induction of chorea and dystonia in parkinsonian primates. Mov Disord 1990;5:3-7.
22. Bezard E, Hill MP, Crossman AR, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 2004;485:159-164.
23. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 1995;10:731-740.
24. Schneider JS, Gonczi H, Decamp E. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms. Brain Res 2003;990:38-44.
25. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 2000;15:459-466.
26. Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naiive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 2003;18:487-495.
27. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 1999;14:744-753.
28. Kuoppamaki M, Al Barghouthy G, Jackson M, et al. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa. Mov Disord 2002;17:1312-1317.
29. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2002;17:1180-1187.
30. Pifl C, Schingnitz G, Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991;44:591-605.
31. Guy W. ECDEU assessment manual. Rockville, MD: U.S. Department of Health, Education and Welfare; 1976. p 534-537.
32. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994; 9:2-12.
33. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1999;290:1034-1040.
34. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394.
35. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
36. Widner H, Defer GL. Dyskinesias assessment: from CAPIT to CAPSIT. Mov Disord 1999;14(Suppl. 1):60-66.
37. Tan LC, Protell PH, Langston JW, Togasaki DM. The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys. Mov Disord 2002; 17:902-909.
38. Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the macaque monkey. J Neurosci Methods 2000;96:71-76.
39. Melamed E, Olanow CW, Nutt JG, Lang AE. Dyskinesias assessment workshop: reports from the working groups. Mov Disord 1999;14(Suppl. 1):69-73.
40. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 2001;58:1660-1668.
41. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 2001;16:642-650.
42. Manson AJ, Iakovidou E, Lees AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:336-337.
43. Rascol O, Arnulf I, Peyro Saint Paul H, et al. Idazoxan, an alpha-2 antagonist, and L-dopa-induced dyskinesias in patients with Parkinson's disease. Mov Disord 2001;16:708-713.
44. Fox S, Silverdale M, Kellett M, et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov Disord 2004; 19:554-560.
45. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999;14:572-584.
46. Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998;51:203-206.
47. Palmer AM, Stephenson FA. CNS drug discovery: challenges and solutions. Drug News Perspect 2005;18:51-57.
48. Penney JB, Young AB. Speculations on the functional anatomy of basal ganglia disorders. Annu Rev Neurosci 1983;6:73-94.
49. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-271.
50. Wichmann T, DeLong MR. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann NY Acad Sci 2003;991:199-213.
51. Scheinin M, Lomasney JW, Hayden-Hixson DM, et al. Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 1994;21:133-149.
52. Rosin DL, Talley EM, Lee A, et al. Distribution of alpha 2C-adrenergic receptor-like inummoreactivity in the rat central nervous system. J Comp Neurol 1996;372:135-165.
53. Holmberg M, Scheinin M, Kurose H, Miettinen R. Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry. Neuroscience 1999;93:1323-1333.
54. Hill MP, Brotchie JM. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. Br J Pharmacol 1999;128:1577-1585.
55. Zhang W, Ordway GA. The alpha2C-adrenoceptor modulates GABA release in mouse striatum. Brain Res Mol Brain Res 2003;112:24-32.
56. Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427.
57. Grondin R, Hadj Tahar A, Doan VD, Ladure P, Bedard PJ. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 2000;361:181-186.
58. Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003;18:872-883.
59. Chase T. Alpha-2A adrenergic antagonistic effects in advanced Parkinson's disease. Rome, Italy: Movements Disorders Congress; 2004.
60. Bacopoulos NG, Redmond DE, Roth RH. Serotonin and dopamine metabolites in brain regions and cerebrospinal fluid of a primate species: effects of ketamine and fluphenazine. J Neurochem 1979;32:1215-1218.
61. Lavoie B, Parent A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 1990;299:1-16.
62. Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5HT, serotonin) and Parkinson's disease: opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 2002; 9(Suppl. 3):1-6.
63. De Deurwaerdere P, Moison D, Navailles S, Porras G, Spampinato U. Regionally and functionally distinct serotonin receptors control in vivo dopamine outflow in the rat nucleus accumbens. J Neurochem 2005;94:140-149.
64. Porras G, De Deurwaerdere P, Moison D, Spampinato U. Conditional involvement of striatal serotonin3 receptors in the control of in vivo dopamine outflow in the rat striatum. Eur J Neurosci 2003;17:771-781.
65. Cossery JM, Gozlan H, Spampinato U, et al. The selective labelling of central 5HT1A receptor binding sites by [3H]5-methoxy-3-(di-n-propylainino)chroman. Eur J Pharmacol 1987;140:143-155.
66. Rick CE, Stanford IM, Lacey MG. Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2C receptors. Neuroscience 1995;69:903-913.
67. Frechilla D, Cobreros A, Saldise L, et al. Serotonin 5HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 2001; 39:288-296.
68. Numan S, Lundgren KH, Wright DE, Herman JP, Seroogy KB. Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res Mol Brain Res 1995;29:391-396.
69. Fox SH, Brotchie JM. 5HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov Disord 2000;15:1064-1069.
70. Waeber C, Palacios JM. Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study. Neuroscience 1989;32:337-347.
71. Reynolds GP, Mason SL, Meldrum A, et al. 5-hydroxytryptamine (5HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br J Pharmacol 1995;114:993-998.
72. Iravani MM, Jackson MJ, Kuoppamaki M, Smith LA, Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Neurosci 2003; 23:9107-9115.
73. Oh JD, Bibbiani F, Chase TN. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol 2002;177:557-564.
74. Bibbiani F, Oh JD, Chase TN. Serotonin 5HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001;57:1829-1834.
75. Fox SH, Moser B, Brotchie JM. Behavioral effects of 5HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998;151:35-49.
76. Fox SH, Brotchie JM. 5HT(2C) receptor antagonists enhance the buhavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur J Pharmacol 2000;398:59-64.
77. Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study). Clin Neuropharmacol 2004;27:58-62.
78. Bara-Jimenez W, Bibbiani F, Morris MJ, et al. Effects of serotonin 5HT1A agonist in advanced Parkinson's disease. Mov Disord 2005;20:932-936.
79. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994;17:73-82.
80. Chassain CEA, Durif FM. Modulation of serotonin receptors in MPTP-lesioned monkeys. Mov Disord 2004;19:412.
81. Chung KA, Carlson NE, Nutt JG. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology 2005;64:1797-1798.
82. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995; 45:1855-1858.
83. Ashby CR Jr, Wang RY. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 1996;24:349-394.
84. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuro-psychopharmacology 1996;14:87-96.
85. Grondin R, Doan VD, Gregoire L, Bedard PJ. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 1999;52:771-776.
86. Hadj Tahar A, Belanger N, Bangassoro E, Gregoire L, Bedard PJ. Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys. Eur J Pharmacol 2000;399:183-186.
87. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004;62:381-388.
88. Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 2004;75:295-297.
89. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995;701:13-18.
90. Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000;23:S86-S91.
91. Calabresi P, Giacomini P, Centonze D, Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000;47:S60-S68.
92. Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res 2003;5:139-146.
93. Betarbet R, Poisik O, Sherer TB, Greenamyre JT. Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Exp Neurol 2004;187:76-85.
94. Nash JE, Johnston TH, Collingridge GL, Garner CC, Brotchie JM. Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-dopa-induced dyskinesia. FASEB J 2005;19:583-585.
95. Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 2005;112:359-391.
96. Rupniak NM, Boyce S, Steventon MJ, Iversen SD, Marsden CD. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Ann Neurol 1992;32:103-105.
97. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
98. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998;13:798-802.
99. Hill MP, Ravenscroft P, Bezard E, et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 2004;310:386-394.
100. Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23:82-85.
101. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
102. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75: 141-143.
103. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999;22:273-276.
104. Braz CA, Borges V, Ferraz HB. Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol 2004;27:25-29.
105. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-661.
106. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-dopa-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-dopa in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2004;188:471-479.
107. Hadj Tahar A, Gregoire L, Darre A, Belanger N, Meltzer L, Bedard PJ. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis 2004;15:171-176.
108. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000;54:1589-1595.
109. Bibbiani FKA, Chase TN. Combined use of NMDA and AMPA antagonists further reduces levodope-induced dyskinesia in MPTP-lesioned primates. Mov Disord 2004;19(Suppl. 9):606.
110. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004;141:765-774.
111. Pertwee RG, Wickens AP. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 1991;30:237-244.
112. Glass M, Brotchie JM, Maneuf YP. Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur J Neurosci 1997;9:199-203.
113. Wallmichrath I, Szabo B. Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 2002; 113:671-682.
114. Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001;85:468-471.
115. Brown TM, Brotchie JM, Fitzjohn SM. Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. J Neurosci 2003;23:11073-11077.
116. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999;2: 358-363.
117. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001;57:2108-2111.
118. Segovia G, Mora F, Crossman AR, Brotchie JM. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Mov Disord 2003;18:138-149.
119. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63:1245-1250.
120. van der Stelt M, Fox SH, Hill M, et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J 2005;19:1140-1142.
121. Mesnage V, Houeto JL, Bonnet AM, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol 2004;27:108-110.
122. Cuello AC, Paxinos G. Evidence for a long Leu-enkephalin striopallidal pathway in rat brain. Nature 1978;271:178-180.
123. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992;15:133-139.
124. Seizinger BR, Grimm C, Hollt V, Herz A. Evidence for a selective processing of proenkephalin B into different opioid peptide forms in particular regions of rat brain and pituitary. J Neurochem 1984;42:447-457.
125. Breslin MB, Lindberg I, Benjannet S, Mathis JP, Lazure C, Seidah NG. Differential processing of proenkephalin by prohormone convertases 1(3) and 2 and furin. J Biol Chem 1993;268:27084-27093.
126. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-118.
127. Duty S, Brotchie JM. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephatin-B, but not preproenkephalin-A, gene expression. Exp Neurol 1997;144:423-432.
128. Cenci MA, Lee CS, Bjorklund A. L-dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;10:2694-2706.
129. Henry B, Crossman AR, Brotchie JM. Effect of repeated L-dopa, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 1999;155:204-220.
130. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 2003;183:458-468.
131. Nisbet AP, Foster OJ, Kingsbury A, et al. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1995;66: 361-376.
132. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di PT. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 2002;61:186-196.
133. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997;42:720-726.
134. Maneuf YP, Mitchell LJ, Crossman AR, Brotchie JM. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol 1994;125:65-71.
135. You ZB, Herrera Marschitz M, Nylander I, et al. Effect of morphine on dynorphin B and GABA release in the basal ganglia of rats. Brain Res 1996;710:241-248.
136. Henry B, Fox SH, Crossman AR, Brotchie JM. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 2001;171:139-146.
137. Klintenberg R, Svenningsson P, Gunne L, Andren PE. Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism. J Neural Transm 2002;109:1295-1307.
138. Samadi P, Gregoire L, Bedard PJ. Opioid antagonists increase the dyskinctic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology 2003;45:954-963.
139. Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994;9:437-440.
140. Manson AJ, Katzenschlager R, Hobart J, Lees AJ. High dose naltrexone for dyskinesias induced by levodopa. J Neurol Neurosurg Psychiatry 2001;70:554-556.
141. Martinez-Mir MI, Probst A, Palacios JM. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience 1991;42:697-706.
142. Ochi M, Koga K, Kurokawa M, Kase H, Nakamura J, Kuwana Y. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 2000;100:53-62.
143. Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 2003;61:S44-S48.
144. Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J Neurosci 2000;20:7782-7789.
145. Morelli M, Pinna A. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci 2001;22:71-72.
146. Bove J, Marin C, Bonastre M, Tolosa E. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 2002;46:251-257.
147. Bibbiani F, Oh JD, Petzer JP, et al. A(2A) antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 2003; 184:285-294.
148. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
149. Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-dopa or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-327.
150. Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-296.
151. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.
152. Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-296.